Finland - finsk - Fimea (Suomen lääkevirasto)

zentiva k.s. - azacitidine - injektiokuiva-aine, suspensiota varten - 25 mg/ml - atsasitidiini

Den Europæiske Union - finsk - EMA (European Medicines Agency)

bluebird bio (netherlands) b.v. - elivaldogene autotemcel - adrenoleukodystrophy - muut hermoston huumeet - treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an abcd1 genetic mutation, and for whom a human leukocyte antigen (hla) matched sibling haematopoietic stem cell donor is not available.

Den Europæiske Union - finsk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - atsakitidiini - leukemia, myeloidi, akuutti - antineoplastiset aineet - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Finland - finsk - Fimea (Suomen lääkevirasto)

sun pharmaceutical industries europe b.v. - azacitidine - injektiokuiva-aine, suspensiota varten - 25 mg/ml - atsasitidiini

Finland - finsk - Fimea (Suomen lääkevirasto)

laboratorios lorien s.l. - azacitidine - injektiokuiva-aine, suspensiota varten - 25 mg/ml - atsasitidiini

Den Europæiske Union - finsk - EMA (European Medicines Agency)

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.